

**REMARKS**

The elected species is claim 11, more specifically claim 13, wherein cisplatin is the antineoplastic agent. The method of carrying the cisplatin is that of claim 5. Thus, the election of species involves poly(propyleneimine) having carboxylate functional groups of a generation 3.5 ethylenediamine core as aggregates of cisplatin and have the cisplatin encapsulated.

All claims of the application are relevant to this species.

Applicants believe that these Remarks constitute a full Response to the October 6, 2003 Office Action. Consideration on the merits is respectfully requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Mark S. Scott', is written over a horizontal line.

Mark S.Scott  
Registration No. 43,101  
Phone: (989) 636-1402

P. O. Box 1967  
Midland, MI 48641-1967

KLK/maw